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Asthma is a heterogeneous disease developed against various stimuli (indoor 
and outdoor allergens, cigarette, air pollution, etc.), associated with airway 
hypersensitivity and characterized by chronic airway inflammation. COVID-19 is a 
disease caused by a coronavirus strain called Severe Acute Respiratory Syndrome-
coronavirus-2 (SARS-CoV-2). There may be some clinical confusions in proper 
diagnostics due to certain similarities of both diseases’s symptoms such as, for 
example, a difficulty of breathing, cough, and shortness of breath. The current data 
on asthma being a risk factor for COVID-19 are controversial. It has been reported 
that asthma is not a risk factor for COVID-19 as the course of COVID-19 in patients 
with asthma is similar to that observed in the normal population. On the other 
hand, a current guidance from the World Health Organization (WHO) suggests 
that asthmatic patients can get more severe illness from COVID-19. Moreover, as 
with all respiratory tract infections, SARS-CoV-2 virus can certainly impair asthma 
control. However, recent studies suggest a potential beneficial effect of corticoste-
roids on SARS-CoV-2 infection as they suppress type II inflammation and restore 
anti-viral immunity. Prolonged use of a high dose of systemic steroids can increase 
susceptibility to infection and the occurrence of systemic side effects. However, 
patients with asthma should definitely continue their prescribed treatment with 
inhaler steroids and other additional medicines they use during SARS-CoV-2 
infection. In asthmatic patients infected with SARS-CoV-2, the most significant 
risk factor is the loss of asthma control and subsequent presentation to healthcare 
centers due to the lack of asthma control. Therefore, the asthmatic patients using 
biological agents are recommended to continue their prescribed treatment such as 
omelizumab, mopelizumab and prolong the treatment intervals during the peak of 
infection.
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1. Introduction
COVID-19 is a disease caused by a novel coronavirus strain [1–10], which has 
been named by the International Committee on Taxonomy of Viruses (ICTV) as 
SARS-CoV-2. It has caused a severe viral pandemic worldwide since March 2020 
[8, 11]. The virus was first reported in Wuhan, China. Its source is thought to be a 
live animal market, namely bats [12]. The transmission is via respiratory droplets 
[8, 9]. The mean incubation period is 2 to 7 days and the main symptoms include 
fatigue, shortness of breath, fever, coughing, loss of smell and taste, sore throat, 
muscle pain, headache, vomiting and diarrhea [2, 13]. The course of disease is 
highly variable. Comorbidities seen in infected individuals are important in terms 
of the healing time, going to intensive care, and affecting mortality. Among these 
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comorbidities, particular conditions such as hypertension, ischemic heart diseases, 
diabetes, and chronic obstructive pulmonary disease represent the most important 
risk factors for a severe course of disease [13, 14].
Asthma is one of the most common chronic respiratory tract diseases [15]. It is 
considered to affect approximately 300 million people across the world. Prevalence 
rates vary to a great extent, ranging from 1% to 18% in children and adults in 
different countries [16]. Asthma exacerbation is an important reason for emer-
gency admission [15, 16]. It is defined by respiratory symptoms such as wheezing, 
shortness of breath, tightness in the chest and/or coughing and expiratory air flow 
limitation. These signs vary in in time. Usually, exacerbations are observed due to 
various factors like allergy or irritants, exercise, change of air or respiratory tract 
infections. Symptoms and airway limitation are frequently resolved with treatment 
or spontaneously and may be absent for weeks or months. On the other hand, such 
exacerbations may be life-threatening, i.e. the disease may have various clinical 
presentations and severities which are specific to each patient [16]. For an effec-
tive treatment and control of the disease, it is important to educate the patient and 
help to cooperate with the doctor. The education includes preparation of a written 
asthma action plan and medical evaluation at regular intervals. A written asthma 
action plan is a document prepared specifically for the patient by the doctor to show 
how to monitor his/her symptoms and respiratory functions at home, and it should 
be reviewed by the physician at regular intervals. This plan helps the patients recog-
nize the aggravation of their asthma and use suitable treatment options [16]. This 
is very important for minimizing asthmatic patients’ visits to healthcare centers 
during the pandemic and decreasing the risk of transmission [16, 17].
In pandemic the patients with asthma should be managed in two groups: the 
patients who have asthma but have not yet contracted COVID-19, and those who have 
asthma and have contracted COVID-19 [18]. COVID-19 and subsequent association 
between asthma and COVID-19 is a challenging clinical condition with more questions 
than answers. However, we can make some predictions based on the available data.
2.  Management of a patient with asthma who has not contracted 
COVID-19
The main objective for patients should be to avoid COVID-19 infection. At first, 
the patient should be informed that asthma does not pose an extra risk for contract-
ing COVID-19 as well as leading to a severe course of disease [19, 20]. Social isola-
tion and adherence to hygiene rules are the most important factors in prevention 
of disease transmission. Patients with asthma are recommended to remain isolated 
in their home environment, if possible. They should be instructed to self-monitor 
symptoms using a PEFmeter [21]. Thus, visits to healthcare centers should be kept 
at minimum. If patients do not have serious problems during this period, scheduled 
visits should be delayed as much as possible and physicians should be consulted 
by telephone, if necessary. In case of any increase in coughing and/or shortness of 
breath, first of all, it should be made sure that the bronchodilators are delivered at 
adequate doses and the bronchodilator device (nebulizer) is used correctly. The 
patients should be instructed by their physician about what to do when their asthma 
gets worse by means of a written action plan. Considering that an asthma patient 
who1 is on a control-visit may be a potential COVID-19 carrier, it is very impor-
tant not to perform a respiratory function test unless it is extremely necessary. 
Otherwise, it is recommended to keep the room very well ventilated, provide the 
test technician with appropriate protective equipment, particularly an N95 mask, 




Approximately 80% of patients with asthma have allergic rhinitis and  
approximately 40% of patients with allergic rhinitis have allergic asthma. It is 
important to keep the symptoms of allergic rhinitis under control for control of 
asthma [22–24]. Patients with allergic rhinitis can also use their nasal steroids 
and antihistamines safely during this pandemic [23, 25]. During the quarantine, 
patients may have trouble gaining access to their medications due to outgoing 
restrictions and risk of contamination. In Turkey, the validity of the medication 
reports for patients with asthma has been extended from March 1st, 2020 by the 
Turkish Ministry of Health and Social Security Institution so that patients can 
obtain their medicines from pharmacies without prescription [8]. The validity of 
disability reports has been also automatically extended. If patients with allergic 
rhinitis do not use their drugs for symptom control especially during the pollen 
season, their sneezing will increase. The same also applies for patients allergic 
to house dust mites. Spring time poses a risk for asthma attacks in patients with 
pollen allergy while similarly prolonged isolation and quarantine is a risk factor for 
an attack and loss of asthma control in asthma patients allergic to house dust mites. 
If patients with pollen allergy follow the rules of isolation and avoid going out, 
their symptoms will be under control due to reduced contact with pollens. These 
patients should ventilate their rooms in the afternoon and, if they have to ventilate 
it in the morning, they should stay in another room. In patients with allergic rhini-
tis who use masks effectively when they go out, exposure to pollens will be reduced 
and thus their symptoms and the need for medications will also be decreased. 
Patients with allergic rhinitis sensitized to house dust mites are unfortunate 
during this period because of a prolonged stay in closed environments. Therefore, 
it is very important that they use their allergic rhinitis medications regularly and 
follow the measures to protect themselves from house dust mites. While hand 
disinfectants containing chlorhexidine are not effective in SARS-CoV-2 [26], they 
may also lead to asthma attacks in those allergic to this chemical [26]. Use of latex 
hand gloves for hand hygiene may also lead to asthma attacks in patients with latex 
allergy, therefore the washing hands with soap and water should be preferred [26].
As a result asthma patients who have not contracted COVID-19 should definitely 
continue their inhaler steroid treatments and additional prescribed medications, 
and should follow the protection and hygiene rules as much as possible even when 
they are clinically stable [8, 16]. Discontinuation of controlling medications leads to 
disease exacerbation, increases the risk of having an asthma attack and eventually 
poses a higher risk for SARS CoV-2 contamination by hospital admission. Doses 
of inhaler steroids should not be reduced even when asthma is under control. The 
disease may also be controlled with non-steroidal treatments in some patients with 
asthma. In these patients, other treatments should be continued without steroids 
or in combination with low dose steroids [18]. Systemic steroids should be used as 
short as possible in patients with severe asthma. Because in long-term use, suscepti-
bility to infection and steroid side effects may occur [15, 18].
3. Management of a patient with asthma who has contracted COVID-19
Pathophysiology of the coronaviruses (CoVs) and asthma comorbidity is com-
plex and many aspects are unknown. In this book chapter we review the available 
literature on the pathogenesis of asthma and COVID-19.
Asthma is characterized by chronic airway inflammation [16], mainly a type 2 
inflammation. Type 2 immunity involves helper T cells (Th 2), type 2 B cells, type 2 
innate lymphoid cells, type 2 macrophages, IL-4 releasing natural killer (NK) and 
natural killer T (NKT) cells, basophils, eosinophils and mast cells [3, 4]. In general, 
Asthma
4
antiviral and allergic responses are two separate branches of immunity and interact 
in a comprehensive network of interactions. Type I IFNs are the family of antiviral 
cytokines that play an important and central role in this network. In asthma, release 
of type I IFNs from bronchial epithelial cells and plasmacytoid dendritic cells is 
disrupted [3, 4].
It is well known that eosinophils play a central role in allergic diseases includ-
ing asthma [4]. The possible effects of eosinophils on CoV are also remarkable. 
Eosinophils have a potential role in enhancing viral clearance and antiviral host 
defense. Recombinant eosinophil-derived neurotoxin (a major eosinophil ribo-
nuclease) is capable of reducing the infectivity of respiratory syncytial virus (RSV) 
In addition, eosinophils can be activated with ssRNA through triggering the TLR-
7-MyD88 signaling pathway, which might result in RSV clearance and limitation 
of virus-induced lung dysfunction. The low prevalence of COVID-19 in asthma 
patients may be due to eosinophils’ defense against the virus. Eosinopenia occurs 
in COVID-19, pathophysiology is unclear [27]. Blockade of eosinophil release from 
bone marrow during acute infection, decreased expression of chemokine recep-
tors or direct eosinophil apoptosis may caused by type 1 IFNs may be responsible. 
There is little indication that eosinophils play a protective or aggravating role during 
SARS-CoV-2 infection. Eosinopenia, however, may be a prognostic indicator for 
more severe SARS-CoV-2 infection [27]. Additionally, it is not known whether 
eosinopenia is a consequence of impaired immunity or biologics intake. The role of 
eosinophils in the course of eosinophilic inflammation associated with SARS-CoV-2 
infection and allergy needs to be investigated further [4].
In theory, asthma as a lung-targeted chronic disease should increase the vulner-
ability of lung tissue to COVID-19 infection and should lead to a worse course 
of COVID-19 and reduced anti-viral immune response. But, interestingly, it was 
reported that asthma produces a type 2 inflammatory cytokines (IL-4,-5 and − 13) 
and accumulation of eosinophils in the airways and their number increases systemi-
cally, what provides a protection against COVID-19 [4]. As with SARS and other 
seasonal coronaviruses, SARS-Cov-2 also uses the cellular receptors of angiotensin 
converting enzyme 2 (ACE2) to invade the cells. Upregulated ACE-2 expression 
increases the sensitivity of receptor-expressing cells to infection. However, ACE-2 
expression in the respiratory tract epithelium is decreased in patients with asthma 
as compared to normal control subjects, and this protects from COVID-19 [4, 5, 28]. 
Allergic diseases do not predispose to COVID-19 and does not increase COVID-19 
severity. Asthma also does not pose a risk to COVID-19, and there is no differ-
ence between asthma patients with and without COVID-19 in terms of hospital 
admission and severity of the course of disease [15, 28–30]. When patients with 
asthma contract COVID-19, they have a disease course similar to that of the normal 
population [15, 31]. But as with all viruses causing respiratory tract infections, 
SARS-CoV-2 is also a risk factor for asthma attacks and disrupts asthma control 
[16, 32]. Despite proper and adequate treatment bronchodilator therapy, patients 
with increased symptoms, additional symptoms and/or contact history should be 
admitted to the hospital and undergo appropriate examination and investigations.
Exacerbation of asthma and allergic rhinitis may also be confused with COVID-
19 clinically [8, 23]. Dry coughs and shortness of breath may be seen asthma, 
allergic rhinitis and COVID-19. Seasonality of symptoms and history of symptom 
development in the presence of exposure to a certain allergic agent are quite helpful 
in the differential diagnosis of allergic rhinitis. Atopy test also supports the diagno-
sis. It is also very important to distinguish between an asthma attack and COVID-19 
infection attack in a patient with a prior diagnosis of asthma as both display inter-
fering symptoms such as shortness of breath and coughing. Therefore, differential 




In addition to the clinical presentation, laboratory findings (such as eosinophil and 
lymphocyte count, C reactive protein, D Dimer) may also be beneficial in the dif-
ferential diagnosis. While presence of lymphopenia and eosinopenia in hemogram 
may favor COVID-19 [8] increased eosinophil levels may indicate asthma. While an 
asthma patient presenting with symptoms such as coughing, shortness of breath, 
wheezing and stridor without any additional finding should be primarily evaluated 
for an asthma attack; considering that everybody may be infected in such a pan-
demic, extra care should be exercised regarding social isolation, distance and the 
use of personal protective equipment for the safety of both patient and healthcare 
personnel [8]. Asthmatic patients who develop weakness, loss of smell and taste 
should have chest X-ray and blood tests for COVID-19 [8].
4. Symptoms of asthma, COVID-19 and allergic rhinitis
Corticosteroids hold a significant place in the treatment of asthma [2]. High-
dose corticosteroids have been used α during the SARS and MERS outbreaks and 
in COVID-19 to suppress lung inflammation during critical illness of infected 
patients. Corticosteroids (inhaled or systemic) can inhibit production of the critical 
antiviral mediators type I and III interferons [3]). At the same time its suppress type 
2 inflammation and their use in COVID-19-associated exacerbation may lead to the 
beneficial effect of secondary restoration of impaired antiviral immunity. However, 
clinical evidence of corticosteroid use in COVID-19 is still insufficient [3].
In patients with asthma who have contracted COVID-19, inhaled corticosteroid 
dose may be increased 4-fold depending on the severity of the disease or use of sys-
temic administration of steroids is recommended [18, 30]. In patients with severe 
asthma, systemic steroid therapy should be used as short as possible, as in asthma 
patients without COVID-19.
Steroid therapy preferably should be taken in the form of metered-dose inhalers 
containing dry powder rather than nebulizers [5, 33]. Metered-dose inhalers are 
ideal devices thanks to their ease of use and low risk of viral transmission, but they 
may not be effective in cases of severe dyspnea, cognitive or neuromuscular disor-
ders and respiratory failure with inadequate inspiratory strength [33]. Dry powder 
inhalers are able to reach the lungs in low inspiratory flow and do not require 
hand-breath coordination (squeezing the inhaler medication at the same time while 
breathing deeply). On the other hand, dry powder inhalers may lead to irritation in 
the airways and coughing, and a by creating aerolization potential viral transmis-
sion is also of question. It is contradictory whether the treatment with a nebulizer 
is risky in terms of viral transmission due to aerosolization [34]. As a result, a 
metered-dose inhalator with a valved reservoir or dry powder inhaler is preferred 
for reducing the auto-aerosolization and spread of the virus [35].
Leukotriene receptor antagonists with their beneficial anti-inflammatory and 
bronchodilator activities may also be added to the treatment of the patients with 
COVID-19 and asthma admitted to the hospital [5, 30, 36].
Azithromycin has been shown to be an effective treatment in decreasing the fre-
quency of exacerbations and improving the quality of life in asthma patients whose 
condition cannot be controlled with standard treatment [31, 37]. Azithromycin 
decreases the risk of COVID-19-related severe outcomes by increasing the IFN 
production associated with a natural antiviral immunity in respiratory tract cells 
[37]. However, azithromycin is not recommended for prophylactic treatment of 
COVID-19 [37].
An asthma patient receiving allergen immunotherapy who is infected with 
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treatment in the absence of any symptoms [38] It has been reported that immune 
response to virus can be improved and cytokine storm can be prevented by this 
treatment [4, 30, 39]. But if there are any signs of respiratory tract infection, it is 
recommended to treat this infection [39].
Use of Anti-IgE, anti-IL-5/IL-5 alfa, anti-IL-4 alfa is not risky for patient with 
asthma who has contracted COVID-19, therefore such medications may be safely 
used to control asthma [30, 40]. Although patients using biologic agents are recom-
mended to continue their treatment. During the period of COVID-19 peak, biologi-
cal agent treatment is applied less frequently. Biological agent therapy continues as 
before when symptoms are improved or COVID-PCR becomes negative [22, 23]. 
Since patients with severe asthma may be at higher risk of severe COVID-19 infec-
tion, they should avoid any activities which may disrupt their asthma control and 
they should use their asthma therapies properly.
In conclusion, asthma does not represent a risk factor for COVID-19 and asthma 
does not adversely affect the course of COVID-19. However, it is extremely impor-
tant to keep asthma under control particularly during the pandemic period. Patients 
with asthma should be recommended to continue to use inhaler steroids that keep 
their asthma under control along with other prescribed medications. Patients 
should be provided with a written emergency action plan because nowadays a 
visit to a healthcare center carries a risk for the SARS-CoV-2 infection. In order to 
prevent the risk of transmission of infection, training should be given on maintain-
ing social isolation and distance, avoiding contact, hand hygiene and correct use 
of masks.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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